{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:25:15Z","timestamp":1790799915034,"version":"4.1.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Stroke"],"published-print":{"date-parts":[[2003,10]]},"abstract":"<jats:p>\n            <jats:bold>\n              <jats:italic>Background and Purpose\u2014<\/jats:italic>\n            <\/jats:bold>\n            We sought to quantify the effects of blood pressure lowering on long-term disability and dependency among patients with cerebrovascular disease.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Methods\u2014<\/jats:italic>\n            <\/jats:bold>\n            We performed a randomized, double-blind, placebo-controlled trial. A total of 6105 participants with a history of stroke or transient ischemic attack in the past 5 years were recruited from 172 hospital outpatient clinics in 10 countries. Subjects were randomly assigned to the following groups: active treatment (angiotensin-converting enzyme inhibitor perindopril [4 mg\/d] for all patients, with the diuretic indapamide added at the discretion of treating physicians) or matching placebo(s). Measurements were disability (defined as a Barthel Index score \u226499\/100) and dependency (a positive response to the following question: \u201cIn the last 2 weeks has the patient required regular help with everyday activities?\u201d).\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Results\u2014<\/jats:italic>\n            <\/jats:bold>\n            The median duration of follow-up was 4 years. At the last available assessment, 19% of the active treatment group and 22% of the placebo group were disabled (adjusted odds ratio, 0.76; 95% CI, 0.65 to 0.89;\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001). Twelve percent of the active treatment group and 14% of the placebo group were dependent (adjusted odds ratio, 0.84; 95% CI, 0.71 to 0.99;\n            <jats:italic>P<\/jats:italic>\n            =0.04). The effects of treatment appeared to be mediated primarily through the prevention of disability and dependency associated with recurrent stroke. Four-year treatment with the study drug regimen would be expected to result in the avoidance of 1 case of long-term disability for every 30 (95% CI, 19 to 79) patients.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Conclusions\u2014<\/jats:italic>\n            <\/jats:bold>\n            Among individuals with cerebrovascular disease, a perindopril-based blood pressure\u2013lowering regimen not only reduced the risk of stroke and major vascular events but also substantially reduced the risks of associated long-term disability and dependency.\n          <\/jats:p>","DOI":"10.1161\/01.str.0000091397.81767.40","type":"journal-article","created":{"date-parts":[[2003,9,9]],"date-time":"2003-09-09T02:30:21Z","timestamp":1063074621000},"page":"2333-2338","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":50,"title":["Effects of a Perindopril-Based Blood Pressure\u2013Lowering Regimen on Disability and Dependency in 6105 Patients With Cerebrovascular Disease"],"prefix":"10.1161","volume":"34","author":[{"name":"PROGRESS","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_1_2","unstructured":"World Health Organization. The World Heath Report 2000: Health Systems: Improving Performance. Geneva Switzerland: WHO; 2000."},{"key":"e_1_3_3_2_2","unstructured":"The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases Injuries and Risk Factors in 1990 and Projected to 2020. Boston Mass: Harvard School of Public Health; 1996."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)04407-4"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.0000012515.66889.24"},{"key":"e_1_3_3_5_2","first-page":"275","volume":"56","year":"2000","unstructured":"Wolfe C. The impact of stroke. Br Med Bull. 2000; 56: 275\u2013286.","journal-title":"Br Med Bull"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90878-9"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7050.147"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.bmb.a072892"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03307-9"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199601000-00005"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06178-5"},{"key":"e_1_3_3_12_2","first-page":"61","volume":"14","year":"1965","unstructured":"Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965; 14: 61\u201365.","journal-title":"Md State Med J"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(89)90065-6"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.30.8.1538"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.31.6.1429"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000108501"},{"key":"e_1_3_3_17_2","unstructured":"Woodward M. Epidemiology Study Design and Data Analysis. Boca Raton Fla: Chapman and Hall\/CRC; 1999: 157\u2013167."},{"key":"e_1_3_3_18_2","first-page":"1647","volume":"17","year":"1999","unstructured":"PROGRESS Management Committee. PROGRESS (Perindopril Protection Against Recurrent Stroke Study): characteristics of the study population at baseline. J Hypertens. 1999; 17: 1647\u20131655.","journal-title":"J Hypertens"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.84.3.351"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/153.1.72"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.27.12.2331"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/026921559601000407"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/09638280050191972"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.6.1694"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.69.4.487"}],"container-title":["Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.STR.0000091397.81767.40","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T21:46:37Z","timestamp":1715550397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.STR.0000091397.81767.40"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2003,10]]}},"alternative-id":["10.1161\/01.STR.0000091397.81767.40"],"URL":"https:\/\/doi.org\/10.1161\/01.str.0000091397.81767.40","relation":{},"ISSN":["0039-2499","1524-4628"],"issn-type":[{"value":"0039-2499","type":"print"},{"value":"1524-4628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10]]},"assertion":[{"value":"2003-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-06-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-09-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}